Skip to main content

Artiva Biotherapeutics, Inc.

ARTV
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001817241

In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 5 open-market purchases and 11 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.

Q3 2025 vs. Q2 2025

How the institutions holding Artiva Biotherapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of ARTV: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders4840−8
Shares18.5M18.2M−355.0K (−1.9%)
Value$27.9M$52.1M+$24.2M (+86.4%)

New holders (6)

Institutions that held Artiva Biotherapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to ARTV in Q3 2025
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC79,147$227.2K0.00%
XTX Topco Ltd47,973$137.7K0.01%
Landscape Capital Management, L.L.C.39,133$112.3K0.01%
Prelude Capital Management, LLC14,302$41.0K0.00%
EverSource Wealth Advisors, LLC159$4560.00%
Cloud Capital Management, LLC11$00.00%

Sold out (14)

Institutions that held Artiva Biotherapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of ARTV in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Samsara BioCapital, LLC291,666$440.4K
Woodline Partners LP283,124$427.5K
Marshall Wace, LLP52,213$78.8K
Acuta Capital Partners, LLC45,456$68.6K
Jane Street Group, LLC44,215$66.8K
Squarepoint Ops LLC41,395$62.5K
Northern Trust Corp34,964$52.8K
Y-Intercept (Hong Kong) Ltd31,567$47.7K
Ground Swell Capital, LLC24,849$37.5K
Jain Global LLC17,171$25.9K
Susquehanna International Group, LLP16,121$24.3K
Deutsche Bank AG3,383$5.11K
Nisa Investment Advisors, LLC329$497
CWM, LLC10$0